244 related articles for article (PubMed ID: 2114100)
1. Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan DS; Nagashima T; Hoshino T; Waldman F; Pawlak K; Sadee W
Biochem J; 1990 Jun; 268(3):725-31. PubMed ID: 2114100
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.
Ullman B; Gudas LJ; Clift SM; Martin DW
Proc Natl Acad Sci U S A; 1979 Mar; 76(3):1074-8. PubMed ID: 108675
[TBL] [Abstract][Full Text] [Related]
3. Guanine for DNA synthesis. A compulsory route through ribonucleotide reductase.
Duan DS; Sadee W
Biochem J; 1988 Nov; 255(3):1045-8. PubMed ID: 3063254
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
5. Deoxyguanosine toxicity in a mouse T lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction.
Gudas LJ; Ullman B; Cohen A; Martin DW
Cell; 1978 Jul; 14(3):531-8. PubMed ID: 99243
[No Abstract] [Full Text] [Related]
6. Demonstration of normal and mutant protein M1 subunits of deoxyGTP-resistant ribonucleotide reductase from mutant mouse lymphoma cells.
Ullman B; Gudas LJ; Caras IW; Eriksson S; Weinberg GL; Wormsted MA; Martin DW
J Biol Chem; 1981 Oct; 256(19):10189-92. PubMed ID: 7024266
[TBL] [Abstract][Full Text] [Related]
7. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
8. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of purine-nucleoside phosphorylase deficiency.
Albert D; Bluestein HG; Willis RC; Nette K; Seegmiller JE
Cell Immunol; 1984 Jul; 86(2):501-9. PubMed ID: 6428752
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
11. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
12. Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts.
Mann GJ; Fox RM
J Clin Invest; 1986 Nov; 78(5):1261-9. PubMed ID: 3490493
[TBL] [Abstract][Full Text] [Related]
13. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency.
Cohen A; Gudas LJ; Ammann AJ; Staal GE; Martin DW
J Clin Invest; 1978 May; 61(5):1405-9. PubMed ID: 96138
[TBL] [Abstract][Full Text] [Related]
14. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase.
Carson DA; Wasson DB; Lakow E; Kamatani N
Proc Natl Acad Sci U S A; 1982 Jun; 79(12):3848-52. PubMed ID: 6808516
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
16. Deoxyribonucleoside triphosphate metabolism and the mammalian cell cycle. Effects of hydroxyurea on mutant and wild-type mouse S49 T-lymphoma cells.
Eriksson S; Skog S; Tribukait B; Wallström B
Exp Cell Res; 1987 Jan; 168(1):79-88. PubMed ID: 3096753
[TBL] [Abstract][Full Text] [Related]
17. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
18. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
19. Correction of purine nucleoside phosphorylase deficiency by retroviral-mediated gene transfer in mouse S49 T cell lymphoma: a model for gene therapy of T cell immunodeficiency.
Foresman MD; Nelson DM; McIvor RS
Hum Gene Ther; 1992 Dec; 3(6):625-31. PubMed ID: 1482702
[TBL] [Abstract][Full Text] [Related]
20. Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiency.
Chan TS
Cell; 1978 Jul; 14(3):523-30. PubMed ID: 99242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
